[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Epilepsy Market Research Report Forecast to 2023

May 2019 | 196 pages | ID: GDD5105E8BBEN
Market Research Future

US$ 4,450.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Introduction

Epilepsy is a disorder of the brain characterized by repeated seizures. A seizure is usually defined as a sudden alteration of behavior due to a temporary change in the electrical functioning of the brain. Normally, the brain continuously develops tiny electrical impulse in an orderly pattern. The rising prevalence of epilepsy diseases and increasing healthcare expenditure drive the growth of the market. However, high per patient treatment cost and regulatory restriction on profitability may hamper the growth of the market.

The global epilepsy market is expected to register a CAGR of 8.20% during the forecast period of 2018 to 2023. In 2017, the market was led by the Americas with a 38.1% share. The market growth in this region is mainly due to the increasing prevalence of epilepsy disorders among the geriatric population. According to the statistics published by the Epilepsy Foundation of America Organization, 1.3 to 2.8 million people were diagnosed with epilepsy disease in the US in 2018.

The global epilepsy market has been segmented based on condition, diagnosis and treatment, end user, and region.

The condition segment is further segmented into drug-resistant epilepsy and others.

The global epilepsy market, by diagnosis and treatment, is segmented into diagnosis and treatment.

The global epilepsy market, by end user, is segmented into hospitals, clinics (family practitioners/ internal medicine), ambulatory surgical centers (outpatient centers), diagnostic centers, and others.

Key Players

LivaNova PLC, GlaxoSmithKline PLC, Eisai Co. Ltd, Pfizer Inc., Medtronic PLC, UCB SA, NeuroPace Inc, GW Pharmaceuticals PLC, Novartis AG, Johnson & Johnson Services Inc., Abbott Laboratories, and others.

Study Objectives
  • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the epilepsy market
  • To provide insights into factors affecting the market growth
  • To analyze the global epilepsy market based on various tools such as supply chain analysis and Porter’s five force analysis
  • To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
  • To provide country-level analysis of the market with respect to the current market size and future perspective
  • To provide country-level analysis of the market for segments by condition, diagnosis and treatment, end user, and region
  • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the epilepsy market
Target Audience
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Government Research Institutes
  • Academic Institutes and Universities
Key Findings
  • The global epilepsy market is expected to reach USD 9,509.20 million by 2023 from USD 5,931.74 million in 2017 and is expected to register a CAGR of 8.20% during the forecast period from 2018 to 2023
  • On the basis of condition, the drug-resistant epilepsy segment accounted for the largest market share and is projected to register a CAGR of 9.07% from 2018 to 2023
  • Based on diagnosis and treatment, the treatment segment accounted for the largest market share and is anticipated to register a CAGR of 7.91% by the year 2023
  • Based on end user, the hospitals segment held the largest market share of 29.3% in 2017 and is projected to register a CAGR of 8.29% during the forecast period
  • The Americas is expected to hold the largest share of the global epilepsy market at a CAGR of 7.77% by 2023
  • Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 8.86% by 2023
Regional Analysis
  • Americas
    • North America
      • US
      • Canada
    • Latin America
      • Brazil
      • Rest of Latin America
  • Europe
    • Western Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Western Europe
    • Eastern Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
      • Saudi Arabia
      • Rest of the Middle East
    • Africa
1 REPORT PROLOGUE

2 EXECUTIVE SUMMARY

3 MARKET INTRODUCTION

3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
  3.3.1 Assumptions
  3.3.2 Limitations
3.4 Market Structure

4 RESEARCH METHODOLOGY

4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model

5 MARKET DYNAMICS

5.1 Introduction
5.2 Drivers
  5.2.1 Rising prevalence of epilepsy amongst the geriatric population
  5.2.2 Increasing cases of brain injuries due to road accidents
  5.2.3 Rising neurological disorders
  5.2.4 Increasing research funding in epilepsy
5.3 Restraints
  5.3.1 Loss of patent protection for branded drugs
  5.3.2 High costs associated with the treatment of epilepsy
5.4 Opportunities
  5.4.1 Entering developing economies

6 MARKET FACTOR ANALYSIS

6.1 Porter’s Five Forces Analysis
  6.1.1 Bargaining Power of Suppliers
  6.1.2 Bargaining Power of Buyers
  6.1.3 Threat of New Entrants
  6.1.4 Threat of Substitutes
  6.1.5 Intensity of Rivalry
6.2 Supply Chain Analysis
  6.2.1 R&D
  6.2.2 Manufacturing
  6.2.3 Distribution
  6.2.4 Marketing & Sales
  6.2.5 Post-Sales Monitoring
6.3 Investment Opportunities
6.4 Pricing Analysis
6.5 Demographic Analysis

7 GLOBAL EPILEPSY MARKET, BY CONDITION

7.1 Overview
  7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy
  7.1.2 Others

8 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT

8.1 Overview
  8.1.1 Diagnosis & Treatment

9 GLOBAL EPILEPSY MARKET, BY END USER

9.1 Overview

10 GLOBAL EPILEPSY MARKET, BY REGION

10.1 Overview
10.2 Americas
  10.2.1 North America
    10.2.1.1 US
    10.2.1.2 CANADA
  10.2.2 Latin America
    10.2.2.1 BRAZIL
    10.2.2.2 REST OF LATIN AMERICA
10.3 Europe
  10.3.1 Western Europe
    10.3.1.1 Germany
    10.3.1.2 France
    10.3.1.3 UK
  10.3.2 Italy
  10.3.3 Spain
  10.3.4 Rest of Western Europe
  10.3.5 Eastern Europe
10.4 Asia-Pacific
    10.4.1.1 Japan
    10.4.1.2 China
  10.4.2 India
  10.4.3 Australia
  10.4.4 South Korea
  10.4.5 Rest of Asia-Pacific
10.5 Middle East & Africa
10.6 Middle East
    10.6.1.1 Saudi Arabia
    10.6.1.2 Rest of Middle East
  10.6.2 Africa

11 COMPETITIVE LANDSCAPE

11.1 Company Market Share Analysis
  11.1.1 Introduction

12 COMPANY PROFILE

12.1 LivaNova PLC
  12.1.1 Company Overview
  12.1.2 Financial Overview
  12.1.3 Products/Services Offered
  12.1.4 Key Development
  12.1.5 SWOT Analysis
  12.1.6 Key Strategies
12.2 GlaxoSmithKline PLC
  12.2.1 Company Overview
  12.2.2 Financial Overview
  12.2.3 Products/Services Offered
  12.2.4 Key Development
  12.2.5 SWOT Analysis
  12.2.6 Key Strategies
12.3 Eisai Co. Ltd
  12.3.1 Company Overview
  12.3.2 Financial Overview
  12.3.3 Products/Services Offered
  12.3.4 Key Development
  12.3.5 SWOT Analysis
  12.3.6 Key Strategies
12.4 Pfizer Inc
  12.4.1 Company Overview
  12.4.2 Financial Overview
  12.4.3 Products/Services Offered
  12.4.4 Key Developments
  12.4.5 SWOT Analysis
  12.4.6 Key Strategies
12.5 Medtronic PLC
  12.5.1 Company Overview
  12.5.2 Financial Overview
  12.5.3 Products/Services Offered
  12.5.4 Key Developments
  12.5.5 SWOT Analysis
  12.5.6 Key Strategies
12.6 UCB SA
  12.6.1 Company Overview
  12.6.2 Financial Overview
  12.6.3 Products/Services Offered
  12.6.4 Key Developments
  12.6.5 SWOT Analysis
  12.6.6 Key Strategies
12.7 NeuroPace Inc
  12.7.1 Company Overview
  12.7.2 Financial Overview
  12.7.3 Products/Services Offered
  12.7.4 Key Developments
  12.7.5 SWOT Analysis
  12.7.6 Key Strategies
12.8 GW Pharmaceuticals PLC
  12.8.1 Company Overview
  12.8.2 Financial Overview
  12.8.3 Products/Services Offered
  12.8.4 Key Developments
  12.8.5 SWOT Analysis
  12.8.6 Key Strategies
12.9 Novartis AG
  12.9.1 Company Overview
  12.9.2 Financial Overview
  12.9.3 Products/Services Offered
  12.9.4 Key Developments
  12.9.5 SWOT Analysis
  12.9.6 Key Strategies
12.1 Johnson & Johnson Services Inc.
  12.10.1 Company Overview
  12.10.2 Financial Overview
  12.10.3 Products/Services Offered
  12.10.4 Key Developments
  12.10.5 SWOT Analysis
  12.10.6 Key Strategies
12.11 Abbott Laboratories
  12.11.1 Company Overview
  12.11.2 Financial Overview
  12.11.3 Products/Services Offered
  12.11.4 Key Developments
  12.11.5 SWOT Analysis
  12.11.6 Key Strategies

13 APPENDIX

13.1 Discussion Blue Print

LIST OF TABLES:

TABLE 1 MARKET SYNOPSIS
TABLE 2 PRIMARY INTERVIEWS
TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2015–2023 (USD MILLION)
TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2015–2023 (USD MILLION)
TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2015-2023 (USD MILLION)
TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2015-2023 (USD MILLION)
TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 13 GLOBAL EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 14 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 15 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY REGION 2015–2023 (USD MILLION)
TABLE 16 GLOBAL EPILEPSY MARKET, FOR CLINICS (FAMILY PRACTITIONERS/ INTERNAL MEDICINE), BY REGION 2015–2023 (USD MILLION)
TABLE 17 GLOBAL EPILEPSY MARKET, FOR AMBULATORY SURGICAL CENTERS (OUTPATIENT CENTERS), BY REGION 2015–2023 (USD MILLION)
TABLE 18 GLOBAL EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION 2015–2023 (USD MILLION)
TABLE 19 GLOBAL EPILEPSY MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 20 GLOBAL PREVALENCE OF EPILEPSY 2015-2023
TABLE 21 GLOBAL INCIDENCE OF EPILEPSY 2015-2023
TABLE 22 AMERICAS: EPILEPSY MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 23 AMERICAS: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 24 AMERICAS: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 25 AMERICAS: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 26 AMERICAS: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 27 AMERICAS: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 28 AMERICAS: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 29 AMERICAS: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 30 AMERICAS: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 31 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 32 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 33 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 34 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 35 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 36 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 37 NORTH AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 38 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 39 NORTH AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 40 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 41 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 42 US: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 43 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 44 US: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 45 US: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 46 US: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 47 CANADA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 48 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 49 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 50 CANADA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 51 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 52 CANADA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 53 CANADA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 54 CANADA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 55 LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 56 LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 57 LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 58 LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 59 LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 60 LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 61 LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 62 BRAZIL: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 63 BRAZIL: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 64 BRAZIL: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 65 BRAZIL: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 66 BRAZIL: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 67 BRAZIL: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 68 BRAZIL: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 69 REST OF LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 70 REST OF LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 71 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 72 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 73 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 74 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 75 REST OF LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 76 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 77 EUROPE: EPILEPSY MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 78 EUROPE: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 79 EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 80 EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 81 EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 82 EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 83 EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 84 EUROPE: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 85 EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 86 WESTERN EUROPE: EPILEPSY MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 87 WESTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 88 WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 89 WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 90 WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 91 WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 92 WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 93 WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 94 WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 95 GERMANY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 96 GERMANY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 97 GERMANY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 98 GERMANY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 99 GERMANY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 100 GERMANY: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 101 GERMANY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 102 FRANCE: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 103 FRANCE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 104 FRANCE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 105 FRANCE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 106 FRANCE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 107 FRANCE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 108 FRANCE: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 109 FRANCE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 110 UK: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 111 UK: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 112 UK: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 113 UK: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 114 UK: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 115 UK: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 116 UK: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 117 UK: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 118 ITALY: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 119 ITALY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 120 ITALY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 121 ITALY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 122 ITALY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 123 ITALY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 124 ITALY: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 125 ITALY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 126 SPAIN: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 127 SPAIN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 128 SPAIN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 129 SPAIN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 130 SPAIN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 131 SPAIN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 132 SPAIN: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 133 SPAIN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 134 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 135 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 136 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 137 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 138 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 139 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 140 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 141 EASTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 142 EASTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 143 EASTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 144 EASTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 145 EASTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 146 EASTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 147 EASTERN EUROPE: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 148 EASTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 149 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY COUNTRY, 2015–2023 (USD MILLION)
TABLE 150 ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 151 ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 152 ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 153 ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 154 ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 155 ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 156 ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 157 ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 158 JAPAN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 159 JAPAN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 160 JAPAN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 161 JAPAN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 162 JAPAN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 163 JAPAN: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 164 JAPAN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 165 CHINA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 166 CHINA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 167 CHINA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 168 CHINA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 169 CHINA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 170 CHINA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 171 CHINA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 172 INDIA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 173 INDIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 174 INDIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 175 INDIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 176 INDIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 177 INDIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 178 INDIA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 179 INDIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 180 AUSTRALIA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 181 AUSTRALIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 182 AUSTRALIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 183 AUSTRALIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 184 AUSTRALIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 185 AUSTRALIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 186 AUSTRALIA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 187 AUSTRALIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 188 SOUTH KOREA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 189 SOUTH KOREA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 190 SOUTH KOREA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 191 SOUTH KOREA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 192 SOUTH KOREA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 193 SOUTH KOREA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 194 SOUTH KOREA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 195 SOUTH KOREA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 196 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 197 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 198 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 199 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 200 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 201 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 202 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 203 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 204 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY REGION, 2015–2023 (USD MILLION)
TABLE 205 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 206 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 207 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 208 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 209 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 213 MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 214 MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 215 MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 216 MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 217 MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 218 MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 219 MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 220 MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 221 SAUDI ARABIA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 222 SAUDI ARABIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 223 SAUDI ARABIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 224 SAUDI ARABIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 225 SAUDI ARABIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 226 SAUDI ARABIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 227 SAUDI ARABIA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 228 SAUDI ARABIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 229 REST OF MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 230 REST OF MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 231 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 232 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 233 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 234 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 235 REST OF MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 236 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)
TABLE 237 AFRICA: EPILEPSY MARKET, BY CONDITION, 2015–2023 (USD MILLION)
TABLE 238 AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2015–2023 (USD MILLION)
TABLE 239 AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2015–2023 (USD MILLION)
TABLE 240 AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2015–2023 (USD MILLION)
TABLE 241 AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2015–2023 (USD MILLION)
TABLE 242 AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2015–2023 (USD MILLION)
TABLE 243 AFRICA: EPILEPSY MARKET, BY END USER, 2015–2023 (USD MILLION)
TABLE 244 AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2015–2023 (USD MILLION)

LIST OF FIGURES:

FIGURE 1 GLOBAL EPILEPSY MARKET: MARKET STRUCTURE
FIGURE 2 RESEARCH PROCESS
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL EPILEPSY MARKET
FIGURE 5 SUPPLY CHAIN: EPILEPSY MARKET
FIGURE 6 GLOBAL EPILEPSY MARKET SHARE, BY CONDITION, 2017 (%)
FIGURE 7 GLOBAL EPILEPSY MARKET, BY CONDITION, 2017 & 2023
FIGURE 8 GLOBAL EPILEPSY MARKET SHARE, BY DIAGNOSIS & TREATMENT, 2017 (%)
FIGURE 9 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2017 & 2023
FIGURE 10 GLOBAL EPILEPSY MARKET SHARE, BY END USER, 2017 (%)
FIGURE 11 GLOBAL EPILEPSY MARKET, BY END USER, 2017 & 2023
FIGURE 12 GLOBAL EPILEPSY MARKET, BY REGION, 2017 & 2023 (USD MILLION)
FIGURE 13 GLOBAL EPILEPSY MARKET SHARE, BY REGION, 2017 (%)
FIGURE 14 AMERICAS: EPILEPSY MARKET SHARE, BY REGION, 2017 (%)
FIGURE 15 NORTH AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 16 LATIN AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 17 EUROPE: EPILEPSY MARKET SHARE, BY REGION, 2017 (%)
FIGURE 18 WESTERN EUROPE: EPILEPSY MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 19 ASIA-PACIFIC: EPILEPSY MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 20 MIDDLE EAST AND AFRICA: EPILEPSY MARKET SHARE, BY REGION, 2017 (%)
FIGURE 21 MIDDLE EAST: EPILEPSY MARKET SHARE, BY COUNTRY, 2017 (%)
FIGURE 22 GLOBAL EPILEPSY MARKET, MARKET SHARE ANALYSIS 2017 (%)
FIGURE 23 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE 2017 (%)


More Publications